{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:13:51Z","timestamp":1792725231061,"version":"4.5.0"},"reference-count":42,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Appl Thromb Hemost"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antiphospholipid Syndrome (APS) is an autoimmune condition that increases thrombosis risk. Although Vitamin K antagonists (VKA) are standard treatment, interest in direct oral anticoagulants (DOAC) has grown. Recent studies evaluated DOAC across all APS subgroups. This review updates our understanding of DOAC's efficacy and safety compared to VKA in preventing thrombotic complications, integrating new findings into the literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review across PubMed\/Medline, Embase, and Cochrane was conducted in accordance with PRISMA guidelines. The quality of randomized controlled trials (RCTs) and cohort studies was assessed using the Cochrane Risk of Bias tool and the Newcastle-Ottawa Scale, respectively. Meta-analysis calculated odds ratios (OR) using the random effect model for arterial and venous thrombotic and bleeding outcomes<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of a total of 2385 records identified, the meta-analysis included 11 studies, comprising 5 RCTs and 7 observational studies, with a combined total of 1813 participants. The analysis revealed no significant difference in the odds of venous thromboembolism (VTE) between DOAC and VKA (OR\u2009=\u20090.80; 95% CI 0.41-1.56). However, a significant increase in thromboembolism recurrence was noted in triple-positive APS patients using DOAC compared to VKA (OR\u2009=\u20093.62; 95% CI 1.10-11.98). The risk of major bleeding was similar between DOAC and VKA (OR\u2009=\u20091.02; 95% CI 0.62-1.68). Additionally, the pooled analysis indicated a higher risk of arterial thrombosis with DOAC (OR\u2009=\u20096.21; 95% CI 2.06-18.76).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Overall, findings suggest DOAC are comparably safe but increase the risk of arterial thrombosis and VTE in triple-positive APS, favoring warfarin for prophylaxis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10760296251364269","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T08:18:27Z","timestamp":1754036307000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluating the Efficacy and Safety of Direct Oral Anticoagulants Compared to Vitamin K Antagonists in Patients with Antiphospholipid Syndrome: Updated Systematic Review and Meta-Analysis"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1549-0941","authenticated-orcid":false,"given":"Lama","family":"Alfehaid","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"},{"name":"Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4077-4521","authenticated-orcid":false,"given":"Nada","family":"Alsuhebany","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"},{"name":"Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3052-5114","authenticated-orcid":false,"given":"Hussah","family":"Albahlal","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0773-4136","authenticated-orcid":false,"given":"Albatoul","family":"Alomran","sequence":"additional","affiliation":[{"name":"Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-5727","authenticated-orcid":false,"given":"Abdulmajeed M","family":"Alshehri","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"},{"name":"Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1651-1158","authenticated-orcid":false,"given":"Mohammed","family":"AlSheef","sequence":"additional","affiliation":[{"name":"King Fahad Medical City, Riyadh, Saudi Arabia"},{"name":"College of Medicine, Alfaisal University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaali","family":"Almutairi","sequence":"additional","affiliation":[{"name":"Drug Safety and Risk Management, Saudi Food and Drug Authority, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,8]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01753.x"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2017.07.006"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-021-01038-2"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.10.019"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-340232"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310395803"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.10.105"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13499"},{"issue":"1","key":"e_1_3_2_10_2","first-page":"31","article-title":"Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study","volume":"115","author":"Martinez C","unstructured":"Martinez C, Katholing A, Wallenhorst C, Freedman SB. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost. 2016 Jan;115(1):31\u201039. doi: https:\/\/doi.org\/10.1160\/TH15-04-0350. Epub 2015 Aug 6. PMID: 26246112.","journal-title":"Thromb Haemost"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2011.01.014"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.715878"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215213"},{"issue":"26","key":"e_1_3_2_14_2","first-page":"2499","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"EINSTEIN Investigators","unstructured":"EINSTEIN Investigators; Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23;363(26):2499\u20102510. doi: https:\/\/doi.org\/10.1056\/NEJMoa1007903. Epub 2010 Dec 3. PMID: 21128814.","journal-title":"N Engl J Med"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15047"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.07.055"},{"key":"e_1_3_2_17_2","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"339","author":"Moher D","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Br Med J. 2009 Jul 21;339:b2535. doi: https:\/\/doi.org\/10.1136\/bmj.b2535. PMID: 19622551; PMCID: PMC2714657.","journal-title":"Br Med J."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(95)00134-4"},{"key":"e_1_3_2_19_2","unstructured":"Wells GA Shea B O\u2019Connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"e_1_3_2_20_2","volume-title":"Mendeley Reference Manager. [Computer software]","author":"Mendeley","unstructured":"Mendeley. Mendeley Reference Manager. [Computer software]. Mendeley Ltd; n.d. Retrieved from https:\/\/www.mendeley.com"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13140"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1230"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(00)00242-0"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30079-5"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-848333"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.7326\/M19-0291"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005808"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/1358863X16668588"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.185132"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203319881200"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203319889156"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2024.03.013"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2024.39.e252"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000001578"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.10.008"},{"issue":"11","key":"e_1_3_2_37_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2016.06.003","article-title":"Bleeding with direct oral anticoagulants vs warfarin: Clinical experience","volume":"129","author":"Eikelboom J","unstructured":"Eikelboom J, Merli G. Bleeding with direct oral anticoagulants vs warfarin: Clinical experience. Am J Med. 2016 Nov;129(11S):S33\u2010S40. doi: https:\/\/doi.org\/10.1016\/j.amjmed.2016.06.003. Epub 2016 Aug 30. PMID: 27586367.","journal-title":"Am J Med"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.056355"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102327"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102328"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000547"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2022.100011"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.120.031007"}],"container-title":["Clinical and Applied Thrombosis\/Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10760296251364269","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10760296251364269","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10760296251364269","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:05:19Z","timestamp":1777385119000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10760296251364269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":42,"alternative-id":["10.1177\/10760296251364269"],"URL":"https:\/\/doi.org\/10.1177\/10760296251364269","relation":{},"ISSN":["1076-0296","1938-2723"],"issn-type":[{"value":"1076-0296","type":"print"},{"value":"1938-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"article-number":"10760296251364269"}}